Screener
4D Molecular Therapeutics FDMT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $512,905 | $566,711 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $14,692 | $11,159 |
| Accrued and other current liabilities | 22,866 | 26,874 |
| Deferred revenue | 360 | 360 |
| Operating lease liabilities, current portion | 5,486 | 5,592 |
| Total current liabilities | 43,404 | 43,985 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's accounts payable?
- 4D Molecular Therapeutics (FDMT) reported accounts payable of $14.69M in Q1 2026.
- How has 4D Molecular Therapeutics's accounts payable changed year-over-year?
- 4D Molecular Therapeutics's accounts payable increased by 253.9% year-over-year, from $4.15M to $14.69M.
- What is the long-term trend for 4D Molecular Therapeutics's accounts payable?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's accounts payable has grown at a 27.4% compound annual growth rate (CAGR), from $11.72M to $30.87M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about 4D Molecular Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude